Dermatology and aesthetics company Sebacia (Duluth, GA) has completed $20 million Series D financing led by existing investors Versant Ventures (San Francisco, CA), Domain Associates (Princeton, NJ), Accuitive Medical Ventures (Fernandino Beach, FL), and Partners Healthcare Innovation Fund (Cambridge, MA). New investors accounted for approximately 60% of the round and include Salem Partners (Los Angeles, CA) and other undisclosed investors. Additionally, the company closed a $16 million debt facility with Hercules Capital (Palo Alto, CA).
Sebacia is developing a microparticle treatment for moderate to severe acne. The company's microparticles are delivered in a topical suspension designed to work with hair removal or pigmented lesion treatment laser systems. The treatment is intended to be a simple, physician-guided, in-office procedure that could provide an alternative to existing therapies, such as oral antibiotics and isotretinoin. The procedure is CE-Marked in Europe and is being evaluated in clinical studies in the United States.
Sebacia intends to use the proceeds from the financing to complete a U.S. pivotal trial with expected results reporting by mid-2018, with submission and FDA response expected by the end of 2018. Further, with CE Mark and market clearance for commercialization in Europe, the company also intends to expand its commercial presence in the European Union.
The company also plans to expand its worldwide patent estate, which includes the seminal selective photothermalysis methods developed by R. Rox Anderson at Massachusetts General Hospital (Boston, MA).
For more information, please visit www.sebacia.com.